India, April 15 -- Galmed Pharmaceuticals Ltd. (GLMD), a clinical-stage biopharmaceutical company, announced on Tuesday a collaboration agreement with Ramot, a technology transfer company at Tel Aviv University, to evaluate the brain-penetrating Aramchol in treating metastatic brain cancer.
Aramchol is a SCD1 inhibitor originally developed to treat liver disease, and was expanded by Galmed for oncological indications including breast cancer brain metastasis. Research published by the Ben-David and Satchi-Fainaro labs at Tel Aviv University indicates that breast cancer brain metastasis is caused by p53 inactivation, inducing metabolic adaptations into tumors. This is accompanied by the upregulation of SCD1, an enzyme needed for lipid synthe...